June 14, 2021 04:29 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Covid19: Maharashtra CM Uddhav Thackeray meets Sarpanches | US FDA denies India’s Covaxin emergency use approval; seeks additional clinical trial data | Mamata welcomes back Mukul Roy to TMC, shuts door for pre-poll turncoats | Sedition case against filmmaker Aisha Sultana for calling Lakshadweep administrator Praful Patel 'bio-weapon' | Yogi Adityanath meets PM Modi amid speculations over change in UP face
US FDA denies India’s Covaxin emergency use approval; seeks additional clinical trial data Covaxin
Image tweeted by @IndianEmbassyTR

US FDA denies India’s Covaxin emergency use approval; seeks additional clinical trial data

India Blooms News Service | @indiablooms | 11 Jun 2021, 11:43 pm

Hyderabad/UNI:India’s indigenous Covid vaccine ‘Covaxin’ developed by Hyderabad-based Bharat Biotech (BB), will be delayed to launch in the US market as US Food and Drug Administration (FDA) asked ‘Ocugen Inc ‘ the US partner of the BB, to pursue a biological Applications (BLA) path for ‘Covaxin,’ which is full approval.

Bharat Biotech had earlier said it and Ocugen Inc, a US-based biopharmaceutical company, have entered into a definitive agreement to co-develop, supply, and commercialise, the India vaccine makers Covaxin for the USA market.

Ocugen, which is working towards the submission of the emergency use application (EUA) in the US, will simultaneously seek authorisation under interim order for emergency use in Canada.

According to Hyderabad-based vaccine maker on Friday, ‘Our US partner, Ocugen, has received a ‘recommendation ‘from the FDA to pursue a Biologics License Applications (BLA) path for COVAXIN®, which is full approval.

All applications have to follow the BLA process, which is the standard process for vaccines, it said.

Therefore, for BLA, data from an additional clinical trial will be required to support the marketing application submission for COVAXIN®, the company said ‘this process will extend our timelines’.

COVAXIN has received EUA’s from 14 countries with more than 50 countries in the process.

No vaccine manufactured or developed from India has ever received EUA or full license from USFDA, the company said.
It will be a Great Leap Forward for vaccine innovation and manufacturing from India when approved, it added.

The Pharma company also said with good herd immunity and a significant percentage of the population vaccinated, the USFDA had earlier communicated that no new emergency use authorization (EUA) would be approved for new Covid-19 vaccines.